Shots:
- Orchard to receive $17.5M up front including $10M in cash & $7.5M as equity investment at a premium to Orchard’s share and is also eligible to receive ~$189.5M as other milestones along with royalties on WW sales
- Pharming has granted WW rights to OTL-105 (ex vivo HSC gene therapy) & will be responsible for clinical development, regulatory filings & commercialization of OTL-105 including associated costs
- Orchard will responsible for the completion of IND-enabling activities and manufacture OTL-105 in pre/ clinical development. Additionally, the companies will investigate the application of non-toxic conditioning regimen for OTL-105 administration
Click here to read full press release/ article | Ref: Orchard | Image: Twitter
The post Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema first appeared on PharmaShots.
